Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Verve PCSK9-inhibitor gene therapy
Other

Verve PCSK9-inhibitor gene therapy

Tracked across 1 events · 12 articles · First seen May 26, 2026 · Last active Jun 07, 2026

Sentiment
85
Attention
8
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
8 85
Tech
VERVE-102 Gene Edit Lowers Cholesterol
Scientists have reported promising results from a groundbreaking gene-editing therapy, VERVE-102, developed by Verve PCSK9-inhibitor gene therapy>>>, a subsidiary of Eli Lilly and Company>>>. This therapy aims to permanently reduce 'bad' cholesterol (LDL cholesterol) after…
Impact: Verve PCSK9-inhibitor gene therapy is the experimental gene therapy that demonstrated significant reductions in LDL cholesterol, potentially transforming the treatment of hypercholesterolemia and coronary artery disease.
May 26, 2026 · 12 articles
Key Actions (1)
60 United States — Food and Drug Administration granted Fast Track designation Verve PCSK9-inhibitor gene therapyVERVE-102 Gene Edit Lowers...
NEWSDESK
Track Verve PCSK9-inhibitor gene therapy live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.